Let's talk about a stock that's already had a wild year and might just be getting warmed up. ImmunityBio Inc. (IBRX) is up a staggering 471% since January. That's the kind of move that turns heads and empties wallets—depending on which side of the trade you're on. The rally has been fueled by some very real, very good news: regulatory momentum for its cancer immunotherapy platform, specifically its bladder cancer therapy called ANKTIVA. This progress has effectively graduated the company from a hopeful biotech startup to a commercial oncology player.
But here's where it gets interesting. The story behind the stock's meteoric rise isn't just about the science anymore. It's starting to look a lot like a classic market mechanics story, where positioning and pressure can take over and write the next chapter.
The Short Squeeze Powder Keg
Beneath the surface of this rally, a pretty dramatic imbalance is building. More than 135 million ImmunityBio shares are currently sold short. That represents over 40% of the company's available shares, or "float." For context, that's an unusually high level of short interest.
Why does this matter? It creates a structural pressure point. Short sellers bet on a stock going down by borrowing shares and selling them, hoping to buy them back later at a lower price. But if the stock goes up instead, they face losses. Eventually, to limit those losses or close their position, they have to buy shares back. When a stock with high short interest starts rising rapidly, it can trigger a chain reaction: rising prices force some shorts to buy to cover, which pushes the price up further, which forces more shorts to cover. This feedback loop is what people call a short squeeze, and it can turn a strong rally into an explosive one.
ImmunityBio's relatively small float and its already intense price momentum only make this risk more pronounced. It's like adding kindling to a fire that's already burning hot.
The Smart Money Is Positioning
While the shorts have been piling in, another group has been quietly building positions on the other side. Some heavyweight hedge funds were buying in before the stock's most recent leg up, suggesting they saw value or catalyst potential that the broader market was slower to recognize.
Renaissance Technologies, the quantitative hedge fund founded by the legendary Jim Simons, increased its stake in ImmunityBio by over 21% in the fourth quarter. Even more notably, Millennium Management, led by Israel Englander, expanded its position by more than 145% in the same period. These aren't small bets by small players. This is institutional capital making a calculated move.
The Stage Is Set for Phase Two
In biotech, rallies driven by regulatory breakthroughs often don't happen all at once. They tend to unfold in phases. The first phase is usually the news itself—the FDA approval or positive trial data—which drives the initial re-rating of the stock. That's what we've largely seen so far with ImmunityBio.
The next phase can be driven by positioning. As the story gains credibility, more institutional investors want in, and the shorts who bet against the story start to get nervous. With extreme short interest, rising institutional ownership from firms like Renaissance and Millennium, and momentum that just keeps building, ImmunityBio now has all the key ingredients that have historically cooked up some of biotech's most memorable, multi-stage rallies.
So, the narrative is shifting. The first leg of this journey was about validating the science and the business model. The next leg could be a brutal lesson in market mechanics, where the shorts who doubted the story are forced to become the buyers who fuel its next surge. It's a classic setup, and for ImmunityBio shareholders, it means the most volatile part of the ride might still be ahead.
